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Abstract
This article reviews the current status of classes of HIV-1 integrase enzyme inhibitors. These classes
include peptide-based inhibitors, natural products, polyhydroxylated aromatics, diketo acids,
naphthyridines, and sulfonated compounds including sulfonic acids. Discussions of structure activity
relationships are presented and include the current overview of the structure-based model, suitable for
the further design and development. To date, the advances in the medicinal chemistry of HIV-1
integrase inhibitors have relied mostly on ligand-based designs leading to most displaying similar
binding interactions within the active site or at the dimer interface. This paves the way for single
enzyme mutations rendering entire compound classes inactive and thus, the requirement for second and
third generation inhibitors with novel modes of binding is apparent. To facilitate future structure-based
drug design efforts, a model of the biologically relevant structure of the HIV-1 integrase enzyme, a
dimmer of dimmers has also been discussed.
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AIDS acquired immunodeficiency syndrome
CAPE caffeic acid phenethyl ester
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CCD catalytic core domain
CTD carboxyl terminal domain
DKA aryl-β-diketoacid
HAART highly active antiretroviral therapy
HCV Hepatitis C virus
HHCC histidine-histidine-cysteine-cysteine
HIV human immunodeficiency virus
IN HIV-1 integrase enzyme
MBSA 2-mercaptobenzenesulfonamides
MSH mercaptosalicylhydrazide
NCI National Cancer Institute
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NTD amino-terminal domain
PHA polyhydroxylated aromatics
RT reverse transcriptase
SAR structure-activity relationship
SQ styrylquinolines
Introduction
The human immunodeficiency virus (HIV), first identified in 1983, is commonly accepted as the
causative agent of acquired immunodeficiency syndrome (AIDS) [1]. The prognosis of AIDS patients
who have full access to current therapies has dramatically changed since the first cases of AIDS were
reported. Prior to the inception of the first anti-HIV drug, AZT [2,3], in 1987 the life expectancy for
AIDS patients was less than 1 year, whereas today the median survival for HIV-positive patients
receiving treatment exceeds 8 years [4]. Moreover, the median survival for patients prescribed current
combination therapies has not been determined, as these were only introduced 8 years ago. This
dramatic change is due to the development of effective therapies, to early detection of HIV-positive
individuals, and a sustained effort to analyse and understand viral resistance mechanisms, which can be
overcome by rational drug development and combination therapy [4].
At present, triple therapy, or highly active antiretroviral therapy (HAART), is the standard
treatment for infection. HAART typically consists of a protease inhibitor or a non-nucleoside reverse
transcriptase inhibitor (NNRTI) in combination with two nucleoside reverse transcriptase inhibitors
(NRTI) [5-10]. These multi-drug combination regimens have made it possible to suppress the
replication of HIV to such an extent that the virus becomes undetectable in infected individuals.
Unfortunately, HAART requires patients to adhere to long-term complicated dosing regimens resulting
in many patients becoming non-compliant.
Despite rapid advances in the treatment of HIV infection, eradication of the virus has failed due to
the persistence of latent HIV-1 in resting memory CD4+ T cells [11-16]. Furthermore, the emergence of
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HIV strains resistant to antiretroviral drugs aimed at any of the aforementioned viral targets is an
inevitable phenomenon. Thus, there is a clear and present need to develop new therapies, which target
alternative steps in the viral cycle.
HIV-1 Integrase as a Potential Target for Antiviral Therapy
An important, yet unexploited potential therapeutic target is the HIV-1 integrase enzyme (IN). IN
is a particularly attractive antiviral target as it is indispensable in the HIV lifecycle and perhaps more
importantly it has no cellular counterparts indicating that specific and non-toxic inhibitors could be
developed [17].
The genome of this retrovirus is encoded as RNA and during the viral lifecycle, after translation
into DNA (by reverse transcriptase), it needs to be integrated into the host genome – this is facilitated
by IN. Specifically, it catalyses two distinct reactions, these being 3′-processing and strand transfer.
During 3′-processing, which occurs in the cytoplasm of the infected cell, the enzyme catalyses the
resection of a 5′-GT dinucleotide from each end of the viral DNA thereby generating the nucleophilic
3′-hydroxyl ends required for strand transfer [18-20]. This water-mediated endonucleolytic cleavage of
the 5′-GT dinucleotides occurs immediately 3′ to a highly conserved CA dinucleotide, any alteration of
this sequence prevents IN from catalysing 3′-processing [21-23].
Following 3′-processing, integrase undergoes a structural change in preparation for the binding of
the acceptor (chromosomal) DNA [24,25]. IN, still bound to the 3’-processed viral DNA, translocates
to the nucleus of the infected cell as a part of a pre-integration complex (PIC), wherein the terminal 3’-
OH of the viral DNA attacks the host DNA [26-29]. Strand transfer is coordinated in such a way that
each of the 3′-hydroxyl ends attack a DNA phosphodiester bond on each strand of the chromosomal
DNA with a five-base-pair stagger across the DNA major groove [4,30,31]. This leaves a five-base
single-stranded gap at each junction between the integrated viral DNA and chromosomal DNA, and a
two-base flap at the 5′-ends of the viral DNA, which are repaired by cellular DNA repair enzymes [4].
HIV IN Structure and Functional Domains
HIV-1 IN is a 32-kDa protein, composed of 288 amino acids. When dissecting the molecular
structure of the HIV-1 IN, three discrete domains can be distinguished, the amino-terminal domain
(NTD), the catalytic core domain (CCD) and the carboxyl terminal domain (CTD).
The NTD encompasses residues 1–50 and has been shown to interact with DNA as part of the IN
complex but does not exhibit DNA binding properties when isolated in solution [32-34]. In keeping
with integrases of retroviruses, retrotransposons, and even many prokaryotic transposable elements, the
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NTD contains a histidine-histidine-cysteine-cysteine motif (HHCC) to which Zn2+ binds in a 1:1
stoichiometry [35-37]. The domain comprises a four α-helix bundle which forms a dimer in solution.
The domains are stabilised by a hydrophobic region and the zinc binding motif, consequently the
mutation of a single residue within the HHCC results in the domain losing structure and DNA binding
ability [32,37].
The catalytic core is structurally remarkably similar to other retroviral integrases and
retrotransposons [38]. This family of DNA-processing enzymes typically contain a canonical Asp, Asp,
Glu motif, which in HIV-1 IN is formed by Asp-64, Asp-116 and Glu-152, with the two aspartic acid
residues forming a coordination complex with a divalent metal [39-42]. Although it is well accepted
that a metal co-factor is required for catalysis, to date no definitive conclusions have been reached
regarding the type, Mg2+ of Mn2+, or number of metal ions required [43,44]. However, it is generally
accepted that Mg2+ is a more likely cofactor given its one million-fold abundance over Mn2+ in cells
[45,46]. Further although the X-ray structures show one metal ion within the active site, it is believed
that the second metal ion comes with DNA potentially coordinating with the carboxylate oxygen atoms
of Glu-152 and possibly Asp-64 [43].
The C-terminal domain is primarily composed of β-strands and is the least conserved domain
among the retroviral integrases [40,47-49]. The isolated C-terminal domain has been shown to bind
DNA in a nonspecific manner and also dimerises when isolated in solution [40]. In addition, this
domain has been implicated in protein–protein interactions [50] as it has been shown to interact with
RT, an interaction which appears to be crucial for RT catalytic activity [51,52].
At present, crystal structures of the NTD [35,36], CCD [53,39,40,38,54-58], CTD [48,49], as well
as the CCD with the NTD [59], and the CCD with the CTD [39], have been reported. However,
crystallisation of the entire enzyme has proven to be difficult and to date no complete X-ray crystal
structure has been reported. Consequently, the relative spatial arrangement of these structural domains,
and their interactions with DNA substrates has remained largely unknown. However, as illustrated in
figure 1, it appears as if the enzyme adopts at least a dimeric conformation in which the active sites of
the opposing units are on opposite sides of the complex. As shown in figure 1, this dimerisation is
mediated by a number of hydrophobic interactions between various secondary structures found at the
dimeric interface, such as alpha helices 1, 3, 5, 6 and beta-strand 3 [60].
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(a) (b)
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Figure 1, (a) and (b) – ribbon and cartoon representations: Dimerisation of the core domains is
mediated by a number of hydrophobic interactions. The primary interactions are between alpha helices
1, 3, 6 and beta-strand 3 which are coloured red, yellow, dark blue, and light blue respectively. The
active-site Mg2+ ion and co-crystallised water molecules are coloured by atom type (PBD code 1QS4).
The residues of the catalytic triad are represented as sticks and coloured by atom type. The core domain
adopts a dimeric formation in which the active-sites of the opposing domains are on opposite faces of
the complex. (c) and (d): The CCDs (dark-blue) of the two units directly involved in catalysis
encapsulate the chromosomal DNA (light-blue) while their NTDs (red) appear to play a crucial role in
the binding and positioning of the chromosomal DNA [61]. Further the CTDs (yellow) of two
catalytically involved units appear to play a dual role binding the viral and chromosomal DNA, while
the NTDs (green) and CTDs (black) of the two units not directly involved in catalysis appear to assist
in the binding and positioning of the viral DNA (yellow). (d) Additional view: ‘Sliced in half’ and
rotated 90 °C to the right.
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In a recently published model (Figure 1, (c) and (d)), it has been proposed that a dimer of dimers
is required for activity [61]. In this model only two complete IN units, one from each dimer, are
directly involved in catalysis, while the other two units provide structural support to the complex and
participate in the binding of the viral DNA [61]. As illustrated in figure 1 (c) and (d), the CCDs (dark-
blue) of the two units directly involved in catalysis encapsulate the chromosomal DNA (light-blue)
while their NTDs (red) appear to play a crucial role in the binding and positioning of the chromosomal
DNA. Further, the CTDs (yellow) of two catalytically involved units appear to play a dual role binding
the viral and chromosomal DNA, while the NTDs (green) and CTDs (black) of the two units not
directly involved in catalysis appear to assist in the binding and positioning of the viral DNA (yellow)
[61].
HIV-1 Integrase Inhibitors
In contrast to RT and PR, the paucity of structural information has hampered structure-based
discovery of selective inhibitors targeted to IN. As a consequence, many groups have turned to
substrate-based drug design and high-through screening of chemical or natural product libraries to
search for novel lead molecules. Such studies have unearthed a plethora of inhibitors based on diverse
scaffolds including substrate-based inhibitors, numerous natural products, polyhydroxylated aromatics,
aryl-β-diketoacids, naphthyridines, styrylquinolines, a number of peptides, and sulfur based analogues.
Substrate-Based IN Inhibitors
Rational design commonly begins with the investigation of compounds that are based on, or
mimic the natural enzyme substrate. Amongst the first substrate-based HIV-1 IN inhibitors reported
were the dinucleotides 5’-pGT-3’ (1, Table 1), which is excised from the 3′-end of the viral DNA
during 3′-processing, and 5’pCA-3’ (2, Table 1), which is immediately upstream [62]. Upon further
investigation three other dinucleotides, 5’pCT-3’, 5’-pAC-3’, and 5’-pAT-3’ (3-5, respectively, Table
1) were also identified as potent inhibitors of IN [62].
Table 1: Sequence and IC50 values of a number of dinucleotide HIV-1 IN inhibitors
Nucleotide Sequence
3’-Processing Inhibition
IC50 (µM)
Strand Transfer
Inhibition IC50 (µM)
1 5’-pGT-3’ 22.0 7.0
2 5’-pCA-3’ 105.0 13.0
7
3 5’-pCT-3’ 8.0 6.0
4 5’-pAC-3’ 6.0 3.0
5 5’-pAT-3’ 7.0 7.0
Unfortunately, small oligonucleotides are rapidly cleaved by cellular nucleases. Consequently a
number of studies were initiated to investigate the inhibitory effects of a number of non-natural
nucleotides. The initial non-natural derivatives, which included a number isodeoxycytosine [27] and
cyclic analogues [63] were essentially inactive. However, further investigations lead to the
development of a number of potent inhibitors which included dinucleotide 6 [64] and the
isodeoxyuracil derivative 7 [65] (Figure 2).
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Figure 2: Structure and activity of the natural substrate-based inhibitor 4, the non-natural derivative 6,
and the isodeoxyuracil derivative 7 against 3′-processing (3′P) and strand transfer (ST).
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Figure 3: The structure and activity of the guanosine quartet Zintevir.
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A number of oligonucleotides have also been identified as potent IN inhibitors [66], however to
date the most potent oligonucleotides reported were a series of analogues composed entirely from
deoxyguanosine and thymidine, known as guanosine quartets [67]. However, these quartets are not
only IN inhibitors, as their primary viral target is gp120. Nevertheless, compound 8 (Zintevir) [67] is
currently in pre-clinical trials.
Small-Molecule Natural Product IN Inhibitors
Over the past several years, a plethora of compounds isolated from natural sources have been
identified as HIV-1 IN inhibitors. As illustrated in figure 4, amongst the first identified were
aurintricarboxylic acid (9) [68], the Fusarium heterosporum isolate equisetin (10) [69], integric acid
(11) [70] from Xylaria sp., several lichen acids of the depside and depsidone families, such as
chloroparellic acid (12) [71] and stictic acid (13) [71], and a number of lignanolides, exemplified by β-
conidendrol (14) [72]. Others include many tetracyclins, such as the DNA binder doxorubicin (15)
[73], antioxidants such as flavones, and a number of compounds isolated from food stuffs such as
curcumin (16) [74], which was isolated from the widely used spice cumin.
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Figure 4: The structure and activity of a number of natural products identified as HIV-1 IN inhibitors.
More recently, a number of biaryl fungal extracts have also been identified as HIV-1 IN inhibitors
(Figure 5). Examples include xanthoviridicatin E (17) [75], which was isolated from Penicillium
chrysogenum as well as isochaetochromin B1 and D1 (18 & 19), extracted from Fusarium species [76].
Also isolated from Fusarium species were a series of oxygenated tetracyclic triterpenoids typified by
integracide A and integracide B (20 & 21) [77]. Other fungal isolates include xerocomic acid (22) [78],
extracted from a strain of Xeromphalina junipericola, hydroxyterphenyllin (23) [78] from Aspergillus
candidus, the polyketide australifunginol (24) [79] from a Cytospora species and a series of
sesterterpenoids such as ophiobolin C (25) [80]. 
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Figure 5: The structure and activity of a number of natural products recently identified as HIV-1 IN
inhibitors.
Clearly, numerous naturally occurring compounds based on extremely diverse scaffolds display
inhibitory effects against HIV-1 IN. Thus, elucidation of the common essential structural and chemical
features required for activity is an extremely onerous task. As a result, many groups have adopted
molecular modelling approaches, such as pharmocophore generation, to determine important three-
dimensional arrangements and essential functional groups needed to effectively interact with the
enzyme [81-89]. However, a consistent theme in a significant number of natural product IN inhibitors
is the presence of polyhydroxylated aromatic moieties. Consequently, a significant amount of research
has focused on identifying and subsequently modifying polyphenolic IN inhibitors.
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Polyhydroxylated Aromatic HIV-1 Inhibitors
The group of polyhydroxylated aromatics (PHAs) embodies the most numerous and diverse class
of HIV IN inhibitors. As illustrated in figure 6, the majority of the PHAs share a common architecture
consisting of two aryl units, one of which contains the 1,2-catechol pattern, separated by a linker
segment. Examples of the class include flavones such as quercetagetin (26) [90], caffeic acid phenethyl
ester analogues (CAPE) (27) [90], and chicoric acids (28) [91,92].
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Figure 6: The structure and activity of quercetagetin (26), CAPE (27), and L-chicoric acid (28). The
majority of the PHAs share a common architecture consisting of two aryl units, one of which contains
the 1,2-catechol pattern, separated by a linker segment.
To date no definitive conclusions regarding the inhibitory action of the PHAs have been reported.
It is unclear whether the hydroxyl moieties act by chelating the active-site magnesium ions or are
simply involved in hydrogen bonding within the catalytic core. However, a co-crystallised structure of
the enzyme core with the catechol-containing 30 (Figure 7) [57], suggests that the PHAs may elicit
their inhibitory effects by causing steric obstruction at the dimer interface, possibly leading to an arrest
in the formation of an enzymatically functional multimeric complex. Unfortunately the precise binding
mode of 30 is unclear as the ligand in this structure is only partially resolved.
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3'P IC50 = 150 µM
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29
3'P IC50 > 240 µM
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OH
OH
Figure 7: Superimposition of the HIV-1 core backbone co-crystallised with the inactive derivative 29
(PBD code 1HYV57; core domain, grey) on the core domain backbone co-crystallised with 30 (PBD
code 1HYZ57; black). It has been proposed that the binding of 30 induces a number of conformational
changes to a number of key active-site residues while binding of 29 does not induce any
conformational changes [57]. However, superimposition of the two structures reveals no significant
conformational changes to any key active-site residues (active-site residues of both 1HYV and 1HYZ
are represented as sticks).
Although a plethora of PHAs have been identified as potent in vitro IN inhibitors [93-95], the in
vivo antiviral effects of a significant number of PHAs can be attributed to non-integrase-dependent
phenomena. For example, the primary antiviral target of the L-chicoric acid analogues is the viral
envelope glycoprotein gp120 [96]. Furthermore, a large portion of the PHAs are cytotoxic which is
believed to result from non-selective binding and, perhaps more importantly, from the formation of
oxidised species, such as semiquinones or orthoquinones, which form protein or possibly DNA adducts
[97,98].
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In an attempt to separate the mechanism of cytotoxicity and IN inhibition a number of
monohydroxylated [95] derivatives as well as methoxy (31, Figure 8) [95] and acetyl protected catechol
analogues [99] were produced, none of which exhibited a significant inhibitory response. Further, as
illustrated by 33 and 34 [93], which were designed to mimic the two distinct rotational isomers of
CAPE, it appears that subtle conformational factors play a significant role in inhibitor binding. This
indicates the Achilles’ heal of the PHAs is the absolute requirement of a catechol moiety.
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Figure 8: The structure and activity of 31 and 32 illustrating the dramatic reduction in activities
resulting from the protection of the catachol moieties. Further the structure and activity of 33 and 34,
which were designed to mimic the two distinct rotational isomers of CAPE indicating that subtle
conformational factors play a significant role in inhibitor binding.
In an order to identify novel PHA inhibitors devoid of the critical catechol functionality a ligand
based molecular modelling approach was adopted from which a number of novel salicylhydrazides
were identified as IN inhibitors (35 & 36, Figure 9) [100]. A structure-activity relationship (SAR) study
of the lead compounds indicated that the two 2-hydroxy moieties may mimic a catechol as the removal
of one or both moieties [100], or separation of the hydroxyls via chain extension of the hydrazine linker
yielded inactive compounds [100]. To investigate the potential binding mode of these compounds three
mercaptosalicylhydrazide compounds (MSHs), 37, 38, and 39 were designed and synthesised. The
MSHs were found to be 300-fold less cytotoxic and exhibited antiviral activity. Further site-directed
mutagensis and molecular modelling studies indicated that the MSHs bind to Cys-65, located in the
active-site, and chelate Mg2+ [100].
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Figure 9: The structure and activity of the salicylhydrazides 35 and 36 identified during a
pharmacophore study [100] and the mercaptosalicylhydrazide compounds (MSHs) 37-39 synthesised in
an ensuing SAR study [100].
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Figure 10: Structure and activity of a number of coumarin-based HIV-1 integrase inhibitors
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Coumarins, exemplified by 40 [101] (Figure 10), are also a novel class of non-catechol-
containing PHA IN inhibitors. An SAR study of over 30 novel coumarins indicated that a coumarin
dimer (41) [101] was sufficient for activity and in general, a hydrophobic linker was required for
retention of potency while hydroxylation of the coumarin ring at positions C4 and C7 increased
potency (42 & 43) [101]. Further, a photoaffinity study, which utilised a number of coumarins
possessing a photo-activatable benzophenone moiety, indicated that binding occurred at the core dimer
interface [102]. suggesting the coumarins exhibit their inhibitory effects by causing a steric obstruction
of the dimer complex [102].
Despite the enormous number of PHA IN inhibitors identified, only a handful of patents have
been filed. To date, the only patented PHAs are the chicoric acids [96], 3,5-dicaffeoylquinic acids
[103], and caffeoyl naphthalenesulfonamides [99]. Two other patented compounds are an amino acid
derivative [95] and the non-viral entry inhibitor lithospermic acid [95], isolated from Salvia
miltiorrhiza. However, all of these compounds have failed to reach clinical trials, presumably due to
poor cellular uptake and non-specific inhibition. Nevertheless, the development of a therapeutically
viable PHA remains an attractive proposition as it is envisaged that a diet rich in natural PHAs such as
chicoric acids and lithospermic acids, commonly found in vegetables such as lettuce, may reduce
therapeutic doses [104].
Aryl-β-Diketoacid IN Inhibitors
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Figure 11: The structure and activity of two members of the DKA family of HIV-1 IN inhibitors.
Of the currently reported classes of HIV-1 IN inhibitors, the aryl-β-diketoacid containing
compounds (DKAs), exemplified by L-731988 (44) [105], are the most developed biological validated
inhibitors. Indeed a member of this class S-1360 (45) [106] was one of the first IN inhibitors to enter
into clinical trials. The DKAs or 4-aryl-3-oxo-2-hydroxybutenoic acids as they adopt this tautomeric
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conformation in solution [107], were independently identified by both the Merck and Shionogi
companies [108-110].108-110
Although the diketo functionality, which is believed to chelate two magnesium ions [111], is an
intrinsic feature of the DKAs it is not sufficient for activity. As typified by compound 46 [112] (Figure
12b) which appears to be the minimum scaffold required for activity, DKAs require an aryl portion and
an acid portion.
O O
O
O
O O
Glu152
O O
Asp64
OO
Asp116
46
3'P IC50 > 100 µM
ST IC50 = 25.0 µM
Aryl region Diketo core Acid region
M2+ M2+
(a) (b)
Figure 12: (a) Co-crystallised structure of the HIV-1 IN catalytic core (a solvent exposed surface is
shown with charged residues highlighted) with 5CITEP (47). The tetrazole moiety occupies the
phosphate binding pocket. The co-crystallised crystal structure discloses minimal interactions between
the ligand and the resolved Mg2+. (b) The structure, activity, and proposed di-metal binding
interactions of 46.
A member of the DKA family, 5CITEP (47, Figure 12a) [54], was subsequently cocrystallised
with the enzyme catalytic core providing the first X-ray crystal structure of an inhibitor in complex
with the active-site [54]. The co-crystal structure of the core with 5CITEP [54] indicates the carboxylic
acid, or in the case of 5CITEP the carboxylic mimic tetrazole, occupies the phosphate bind-pocket
forming interactions with Lys-156 and Lys-159, whilst the aryl portion occupies a hydrophobic region
of the active-site. However, the 5CITEP co-crystallised crystal structure disclosed minimal interactions
between the ligand and the resolved Mg2+.
In general, the DKAs are characterised by an ability to afford preferential inhibition of strand
transfer (ST) versus 3-processing (3’-P). The high selectivity for the strand-transfer reaction indicates
that the DKAs bind to the enzyme following 3’-processing [4]. This inhibitory response is generally
Lys-156
Lys-159
Glu-152
His-67
(47)
Phosphate-
binding
pocket
Asp-64
Asp-166
Mg2+
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believed to be dependent on the presence of a divalent metal ion(s), which are chelated by the diketo
moiety subsequently blocking DNA substrate binding [113,43,407,114]. Support for such a hypothesis
is provided by the lack of inhibitory action elicited by the DKAs in the absence of Mn2+ or Mg2+ [115].
However, the 5CITEP cocrystallised crystal structure discloses minimal interactions between the ligand
and the resolved Mg2+. Thus, there are growing and popular notions in support of a two-metal ion
theory, which is a typical feature of various DNA binding enzymes such as Hepatitis C virus (HCV)
polymerase [43,111].
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3'P IC50 > 100 µM
ST IC50 = 0.1 µM
Antiviral Activity CIC95 = 1.1 µM
COOH
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3'P IC50 > 1000 µM
ST IC50 = 0.48 µM
Antiviral Activity CIC95 = 2.3 µM
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3'P IC50 > 100 µM
ST IC50 = 29.0 µM
COOH
O OH
HO
HO
51
3'P IC50 = 3.9 µM
ST IC50 = 1.1 µM
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Figure 13: Structure and activity of a number of DKA inhibitors.
A number of structure-activity-relationship (SAR) studies have revealed that the aryl portion of
the DKAs can accommodate a diverse range of substituents. It appears as if the most significant
increases in whole cell activity and reduction of cytotoxicity can be gained with the introduction of
hydrophobic substituents on the aryl moiety such as benzyloxy, benzyl, or phenyloxy at the 3, and 3,5-
positions (48 [112] & 49 [105], Figure 13). However, as illustrated by 50 [116], the size of these
substituents appears to be limited and if hydrophilic substituents are introduced selective inhibition of
strand-transfer is removed 51 [117] suggesting such analogues may elicit there inhibitory response via
a slightly different mechanism.
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Figure 14: Structure and activity of a number of DKA inhibitors with 53 illustrating whole cell activity
can be increased with the addition at C2.
Slight improvements in the antiviral activity of the mono-substituted variants, exemplified by 52
[118] (Figure 14), can be gained with the introduction of a halogen atom at the 2'-position on the distal
benzene ring, while halogen introduction at the 3'-position and the 4'-position leads to no increase or a
significant loss in activity respectively [118]. Further, slight increases in whole cell activity can be
achieved with the introduction of small substituents such as methoxy (53, Figure 14) [118], ethoxy, and
isopropoxy at the 2-position [117,118].
Although it is established that substituents at the 3, 4, or 5 positions on the aryl portion play a
crucial role in the inhibitory process, it is unclear what electronic and chemical properties of such
subsitituents are required to elicit potent antiviral effects. Replacement of the benzyloxy group on 49
[118] (Figure 13) with a benzoylamino group [118] reduces potency by approximately 100-fold.
However, substituting the benzyloxy substituent with an azidomethyl group [119] reduces potency only
by approximately 4-fold. Further quinoline and ferrocenyl groups were poorly tolerated leading to
inactive or cytotoxic inhibitors (54 & 55, Figure 15) [112]. Moreover, while a number of the indole
derivatives exhibited potent in vitro activity, the majority displayed limited antiviral activity and the
select few analogues displaying in vivo inhibition (e.g. 56 Figure 15) [112,120] were cytotoxic.
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3'P IC50 > 100 µM
ST IC50 > 100 µM
Antiviral Activity CIC50 > 100 µM
55
3'P IC50 = 11.5 µM
ST IC50 = 0.8 µM
Antiviral Activity; Cytotoxic
56
3'P IC50 >100 µM
ST IC50 =1.4 µM
Antiviral Activity; Cytotoxic
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Figure 15: Structure and activity of a number of DKA variants.
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In keeping with the indole DKAs, purine (57 & 58, Figure 16)121 and pyrimidine (59 & 60) [122]
analogues displayed potent in vitro activity, reduced in vivo activity and reduced strand-transfer
selectivity. However, the reduction of selectivity of these analogues is not expected as they mimic the
natural substrate.
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3'P IC50 = 35.1 µM
ST IC50 = 4.1 µM
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3'P IC50 = 30 µM
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ST IC50 < 0.6 µM
Antiviral Activity IC50 > 100 µM
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Figure 16: The structure and activity of the purine 57 & 58, [121] and pyrimidine 59 & 60, [122] DKA
analogues.
It is apparent that the subsitituent orientation relative to the diketo acid functionality is significant.
As illustrated by compounds 61 to 65 [118], (Figure 17) potency increases as the angle between the two
lines extending from the benzyl and diketoacid moiety increases from 60° to 120° and decreases as the
angle exceeds 120°.
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61
3'P IC50 > 100 µM
ST IC50 = 5.7 µM
CIC95 > 50µM
62
3'P IC50 > 100 µM
ST IC50 = 0.2 µM
CIC95 = 46.1 µM
63
3'P IC50 > 100 µM
ST IC50 < 0.1 µM
CIC95 = 1.1 µM
64
3'P IC50 > 100 µM
ST IC50 < 0.5 µM
CIC95 = 3.0 µM
65
3'P IC50 > 100 µM
ST IC50 < 0.5 µM
CIC95 = 12.5 µM
Figure 17: A number of DKA derivatives illustrating potency increases as the angle between the two
lines extending from the benzyl and diketoacid moiety increases from 60° to 120° and decreases as the
angle exceeds 120°.
In contrast to the aryl portion of the DKAs, the central diketo moiety has received considerably
less attention with the only major study investigating the effect of elongating the diketo group from a
2,4-dioxobutanoic acid to a 2,4-dioxo-5-hexenoic acid [123]. This extension was conceived as a result
of partial superimposition between the cinnamoyl group of various natural and synthetic IN inhibitors
(Figure 18). One of the highly potent compounds from this series, 66 [123] displayed moderate in vitro
activity against strand-transfer and 3’-processing, however, surprisingly 66, showed remarkable
antiviral activity, each with EC50 values of 1.5 µM, similar to the most potent IN inhibitors reported.
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66
3P IC50 = 7.9 µM
ST IC50 = 7.0 µM
Antiviral activity = 1.5 µM
Figure 18: The design principle behind the dioxohexenoic acids and the structure and activity the most
active member of the series 66.
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An additional variation of the DKAs includes a number of dimeric acids, these inhibitors were
designed on the hypothesis that two diketo moieties could simultaneously bind to the two divalent
metal ions within the IN active-site. As a whole, the dimeric derivatives displayed reduced strand-
transfer selectivity and the initial dimeric acids, 67 [112], 68 [112], and 69 [112], displayed limited
antiviral activity (Figure 19).
67
3'P IC50 = 7.8 µM
ST IC50 = 1.8 µM
EC50 = 90 µM
68
3'P IC50 = 30.0 µM
ST IC50 = 2.7 µM
EC50 = 130 µM
69
3'P IC50 = 82.0 µM
ST IC50 < 6.5 µM
EC50 = 77.5 µM
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Figure 19: The structure and activity of the first dimeric DKA analogues.
Second generation dimeric DKAs include a number of amide (70, Figure 20) [43] or benzyl 71
[43] linked analogues. Unfortunately, the majority of the amide-linked derivatives were found to be
cytotoxic and it is unclear what effects linker geometry has on activity [43]. In contrast, the benzyl-
linked diketoacids were considerably less toxic, however, the majority displayed minimal anti-viral
activity.
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HO COOH HO COOH
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70
3'P IC50 = 5.3 µM
ST IC50 = 0.2 µM
71
3'P IC50 = 5.3 µM
ST IC50 = 0.2 µM
Figure 20: Structure and activity of the second generation dimeric DKAs 70 and 71.
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An additional series of dimeric based DKA analogues were developed based on the premise that
alkylation at the 1-position with a benzyl group to obtain 1,3-disubstituted compounds115 would afford
the geometric requirements for optimal IN inhibitory activity. This approach proved valid with the two
1-p-fluorobenzyl-derivatives 74 & 75 (Figure 21) displaying considerably lower effective
concentrations than the unsubstituted counterparts (72 & 73) [115]. Furthermore 75 is the most potent
bifunctional diketoacid derivative reported to date.
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Figure 21: Structure and activity of the bifunctional quinolonyl DKA derivatives 72-75. Further these
compounds highlight the need for a free carboxylic acid moiety.
Unfortunately, the 1,3-diketoacid functionality is biologically labile, giving rise to the derivatives
containing diketoacid bioisosteres. A number of diketoacid bioisosteres have been shown to be
tolerated on the acid side of the scaffold, these include diketotriazole 45 [106], diketotetrazole 47 [54],
keto-iminoacid 76 [124] and diketopyridine [125].
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Figure 22: Structure and activities of a number of HIV-1 IN inhibitors possessing diketoacid
bioisosteres.
However, it appears that the size of the heteroaryl ring is limited as various substituted tetrazole
analogues (77, 78, and 79, Figure 23) [112] were devoid of activity. A possible explanation for this loss
of activity arises from inspection of the 5CITEP co-crystallised structure (Figure 12), which infers that
the tetrazole ring occupies the relatively polar and confined phosphate-binding pocket [54]. Further, as
illustrated by compound 80 (Figure 23) [124], it appears that an optimum distance between
diketomimetic atoms must be maintained.
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Figure 23: Structures and activities of compounds containing substituted tetrazole moieties and the
structure of the pyrazole containing derivative 80.
Naphthyridine IN Inhibitors
In order to mimic the diketoacid motif three functional regions are required, a ketone mimic, an
enolisable ketone, and carboxyl oxygen, all of which adopt a coplanar conformation with the aryl
portion of the DKA scaffold. Based on this rational, it was hypothesised that a similar arrangement of
key hydroxyl groups could be achieved by a 1,2-catechol and by incorporating an oxygen bridge,
coplanarity between to two phenyl rings could be achieved (81, Figure 24) [126]. Unfortunately, as
outlined previously 1,2-catechols are biologically labile producing toxic metabolites, while coplanar
polyaromatic ring systems typically exhibit poor physical properties [127]. However, based on previous
SAR studies, it was proposed these limitations could be alleviated with the removal of the bridgehead
carbon and substitution of one of the catechol hydroxyl groups with an aromatic nitrogen [126].
Furthermore, it was anticipated that resulting loss of coplanarity could be re-established with the
incorporation of a heteroatom at an appropriate position on the aryl ring. These considerations led to
the synthesis of a number of potent [1,6]naphthyridine analogues (82 & 83, Figure 24) [126].
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Figure 24: Structures and activities of a number of HIV-1 IN inhibitors possessing diketoacid
bioisosteres. The atoms of the diketoacid bioisosteres are with the dotted lines.
Extensions of the 8-hydroxy-[1,6]naphthyridine series lead to the 8-hydroxy-[1,6]naphthyridine-
7-carboxamide derivatives (84, Figure 25) [128]. Significant improvements in both intrinsic potency
and pharmacokinetic properties were obtained with the addition of polar functionalities, such as uracils,
amides, and heterocyles, at the 5-position on the naphthyridine backbone [128]. A member of this
series, L-870810 85 [129,28] entered phase I/II clinical trails and although phase II trials were halted
due to liver and kidney toxicity another member of this series L-870812 86 [128] is currently still in
trials.
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Figure 25: The structure and activity of the the 8-hydroxy-[1,6]naphthyridine-7-carboxamide
derivatives 84-86.
Styrylquinolines IN Inhibitors
A number of heterocyclic IN inhibitors which overlay the 8-hydroxy-[1,6]naphthyridine-7-
carboxamide pharmacophore have been identified. Amongst the first reported were the styrylquinolines
(SQs), exemplified by compound 87 [130] (Figure 26) In contrast to the 8-hydroxy-[1,6]naphthyridine-
7-carboxamides the SQs display non-integrase dependant antiviral activity and reduced selective
inhibition of strand-transfer [131]. It has been demonstrated that the SQs specifically and efficiently
inhibit in vitro nuclear import of IN suggesting that they inhibit the interaction between the enzyme and
the cellular factor required for its nuclear import [131].
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Figure 26: Structure and activity of the styrylquinoline derivatives 87 and 88 (FZ-41) which is poised
to enter clinical trials.
Unlike the PHAs, the catechol moiety of 87 does not induce toxicity nor is its crucial for activity
[132]. A substantial amount of SAR data relating to the SQs has been complied [133-136,130] and it is
evident that numerous aryl moieties such as furan, thiophene, 4-nitrobenzene, and pyridine are well
tolerated on the catachol side of the SQ scaffold [132]. In contrast to the catachol portion, variations to
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the linker functionality are poorly tolerated [133]. Further, as expected, removal [134], protection [130]
or extension [136] of the carboxylic acid functionality was detrimental to activity. An additional
variation to the SQ scaffold theme was a series of styrylbenzofuran derivatives [135], however, these
derivatives were considerably less active than their quinoline counterparts. However, a significant
increase in activity, and unfortunately cytotoxicity, can be achieved with the introduction of the 3,4,5-
trihydroxybenzene moiety [132], yet, methyl protection of one of these hydroxyls results in the
dramatic reduction of cytotoxicity, so much so that compound 88 [132] (FZ-41, Figure 26) is poised to
enter clinical trials.
More recently, 4-quinolone-3-carboxylic acid was identified as a promising masked diketoacid
scaffold. Significant improvements in the antiviral activity of lead compound 89 [127] (Figure 27) were
achieved with the introduction of 2-fluoro and 3-chloro substituents into the distal benzene ring and
alkylation of the quinolone nitrogen with a hydroxyethyl moiety 90 [127]. Further, the introduction of a
methoxy group at the 7-position of the quinolone ring of and an isopropyl group at the 1S-position of
the hydroxyethyl 91, JTK-303 [127] moiety led to a far more potent inhibitor which is currently under
phase I/II clinical trials.
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Figure 27: Structure and activity of the 4-quinolone-3-carboxylic acid derivatives 89, 90 and 91 (FZ-
41) which is poised to enter clinical trials.
Peptide Inhibitors of HIV-1 Integrase
Recent advances in peptide synthesis and combinatorial chemistry have resulted in the generation
and screening of peptide libraries becoming an essential tool in the drug discovery process. However,
surprisingly, only a handful of peptides or peptidomimetics have been identified as IN inhibitors.
The first peptide IN inhibitor isolated from a combinatorial library was the hexapeptide 92 [137]
(Figure 28) During an ensuing SAR study of 92, an number of dimer analogues possessing variable
linkers, such as L-homolanthionine 93 [138] or L-djenkolic acid 94 [138], were synthesised. Of these
compounds the dithiomethylene linked dimer 94 showed an approximately 20-fold higher potency
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compared to the monomer indicating that the dimeric peptide may act as a bivalent inhibitor,
simultaneously occupying neighbouring catalytic sites.
His Cys Lys Phe Trp Trp NH2
92
3'P IC50 = 102 µM
ST IC50 = 90 µM
His Gly Lys Phe Trp Trp NH2
(CH2)2
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S
CH2
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ST IC50 = 6.5 µM
S
CH2
Figure 28: Structure and activity of the peptide base inhibitors 92-94.
Additional IN peptides include Indolicidin (95, Table 2) a tryptophan rich 13-mer natural
antibacterial peptide [139,140], a 33-mer known as I33 [141], and a number of 7-mer derivatives
exemplified by 96 and 97 (Table 2) which were identified from the random screening of a heptapeptide
phage-display library [142].
Table 2: Sequence and activity of the peptide based IN inhibitors 95-97.
Peptide Sequence
3’-Processing Inhibition
IC50 (µM)
Strand Transfer
Inhibition IC50 (µM)
95 ILPWKWPWWPWRR-NH2 60 57
96 HLEHLLF 0.1 13
97 FHNHGKQ 1.0 4.9
Recent studies have shown that the catalytic activity of IN is inhibited in vitro by HIV-1 reverse
transcriptase (RT) [143]. In a random screen of HIV-1 RT derived peptides two 20-residue-long
peptides 98 [143] and 99 [143] were identified as possessing anti-IN activity (Table 3).
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Table 3: Sequence and activity of RT derived IN inhibitors 98 and 99.
Peptide
RT-Derived
Sequence
Position in RT
(residue no.)
3’-Processing
Inhibition
IC50 (µM)
Strand Transfer
Inhibition
IC50 (µM)
98
KILEPFRKQNP
DIVIYQYMD
Palm (133-185) 4.8 4.5
99
ELVNQIIEQLIK
KEKVYLAW
RNase H (516-535) 6.9 5.0
As outlined previously the catalytic core dimerises through mutual interactions between a number
of secondary structures, such as alpha helices 1, 3, 5, 6 and beta-strand 3 [60]. Consequently, two
synthetic peptides, INH1 [144] which corresponds to α1-helix residues 93-107 and compound INH5
[144], corresponding to α5-helix residues 167-187, were synthesised. Both of these compounds
exhibited inhibitory effects with INH5 displaying IC50 values of 85 nM and 60 nM for 3’-processing
and strand transfer activity respectively [144]. More recently, the mimics of all the interfacial
secondary structures were synthesised. Although shorter than the initial mimics, the α1 (100 Table 4)
[60], and α5 101 [60] derivatives along with α-6 mimic 102 [60] displayed potency activity against 3’-
processing. Further, protein crosslinking experiments conducted in the presence of the α1, α5, and, α5
indicated the reduced amounts of dimer-core domains were formed indicating that these peptides
prevent dimerisation of the IN core domains [60].
Table 4: Sequence and activity of RT derived IN inhibitors 100 and 102.
Peptide SecondaryStructure Sequence
3’-Processing
Inhibition IC50
(µM)
100 α1 Q
95ETAYFLLKLAGRWP109-
CONH2
3.5
101 α5 H
171LKTAVQMAVFIHNFKR187-
CONH2
3.0
102 α6 A196GERIVDIIATDIQ210-CONH2 2.0
Sulfonated HIV-1 Integrase Inhibitors
Diverse arrays of sulfur containing compounds such as sulfonates, sulfones, and sulfides, have
been identified as HIV-1 IN inhibitors, however with respect to quantity, the most important class is the
sulfonamides. Sulfonamides are well known antimicrobial drugs with a well established safety profile
and are extensively used in the treatment of Pneumocystis carinii pneumonia, a leading cause of
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morbidity and mortality in AIDS patients. Consequently, a number of studies have focused on
identifying sulfonamide based IN inhibitors, with a number of structurally diverse derivatives identified
(103-105 Figure 29) [145].
H
N
S
O
O
S
H
N
O O N
N
103
3'P IC50 = 28.6µM
ST IC50 = 14.0 µM
H
N
S
O
O
S
H
N
O O N N
S
104
3'P IC50 = 24.0 µM
ST IC50 = 19.0 µM
HN
S
H
N
O O N
N
NN
NH2
105
3'P IC50 = 48.3 µM
ST IC50 = 13.7 µM
O
Figure 29: Structure and activity of a number of sulfonamide based HIV-1 IN inhibitors.
Amongst the more potent derivatives were a series of 2-mercaptobenzenesulfonamides (MBSAs),
typified by 106 [146] (Figure 30). The majority of the MBSAs share a common architecture consisting
of aryl units, one of which possesses a 2-mercapto moiety, separated by a sulfonamide-heteroaryl
linker. SAR studies of the MBSAs indicated that various hydrophobic functionalities such as butane,
were tolerated on the heteroaryl side of the scaffold [146]. Moreover, the introduction of a 4-
chlorophenyl amide substituent on the mercaptophenol ring increased activity, however, crucial to
activity was the presence of a free mecapto moiety [146].
Although number of MBSAs displayed potent in vitro activity, they were found to be
metabolically unstable. In an attempt to improve stability, a number of cyclic derivatives were
produced (107 & 108 Figure 30) [147]. Unfortunately, none of the 3-aroyl-1,1-dioxo-1,4,2-
benzodithiazines displayed potent activity, however, a number of these derivatives displayed
significant differential potencies against the IN mutant C65S, versus the wild type enzyme, suggesting
that these compounds potentially interact with C65, which in close proximity to the highly conserved
catalytic triad [147].
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Figure 30: Structure and activity of the 2-mercaptobenzenesulfonamide 106 and the 3-aroyl-1,1-dioxo-
1,4,2-benzodithiazines derivatives 107 and 108.
The lack of potency displayed by the cyclic sulfonamide derivatives is believed to be primarily
due to the lack of a free mercaptoaryl group. The mercapto moiety is a well know hydroxy isostere and
is present in a number of IN inhibitor such as 109 (figure 31) [100] and the phenyldipyrimidine
analogue 110 V-165 [148] which is currently in preclinical trials. As with the cyclic sulfonamides,
protection of the free mercapto moieties of 110 yielded an inactive compound (111, Figure 31) [148].
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Figure 31: Structure and activity of the mercapto containing derivative 109 and 110 in addition the
protected analogue 111.
In keeping with sulfonamides, sulfone based compounds have a well established safety profile
with a number of sulfone derivatives used in the treatment of malaria. A handful of sulfone-based
compounds have been identified as IN inhibitors, the most potent being the geminal disulfonates,
exemplified by 112 [148] (Figure 32) Further, a number of relatively simple diarylsulfones,
exemplified by compound 113 [149] were identified in the screen of a National Cancer Institute (NCI)
sulfone drug repository. However, a number of diarylsulfones have previously been reported as RT
inhibitors, thus giving a possible explanation to their antiviral activity [150].
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Figure 32: The structure and activity of the geminal disulfonate 112 and the disulfone 113.
Naphthalenesulfonic Acids as Potential HIV-1 Integrase Inhibitors
Amongst the very first IN inhibitors reported was the polyanionic sulfonate suramin (114) [151-
155] (Figure 33). A substantial number of bis-naphthalenesulfonic acids derivatives such as Suramin,
have previously reported as HIV-1, and HIV-2 RT inhibitors [154,156-159,155].
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Figure 33: The structure and activity of the polyanionic sulfonate suramin.
Despite the potent anti-IN activity of suramin, and the in vivo activity displayed a number of
naphthalenesulfonic acid analogues, to date, only a handful of derivatives, such as the moderately
active monomers 115 [160], 116 [160], (Figure 34) and the active derivative 117 (Y3) have been
identified as HIV-1 inhibitors. In addition to Y3, two other naphthalenesulfonic acids, 118 (Y1) [161]
and 119 (Y2)[161], were identified using a three-point pharmacophore to screen the NCI three-
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dimensional database while an additional derivative 120 (Y4) [161] was synthesised in a insuring SAR
study of the Y3 series.
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Figure 34: Structure and activity of a number of naphthalene sulfonate HIV-1 integrase inhibitors.
No definitive conclusions regarding the mechanisms by which the naphthalenesulfonic acids
inhibit IN have been reported, yet there is a consensus that they may reside within a third and as yet
unexploited binding-site. In a co-crystallised structure of the avian sarcoma virus (ASV) core domain,
which shares a 24% sequence homology with HIV-1 IN and 3-D structural alignment RMS deviation of
1.4 Å [162,54] Y3 resided within a pocket removed from the active-site [161]. However, at present,
there is no structural information of any HIV-1 IN-inhibitor complex that binds in this manner.
The Requirement for Second and Third Generation IN Inhibitors
After a decade of research the first-generation IN inhibitors have been patented [164] and are
entering clinical trials. However, continual cell-based viral exposure of a number of the most promising
inhibitors in cells such as L-870812 has resulted in the emergence of a number of resistant strains
[163]. Further, the current generation of IN inhibitors all appear to display similar binding interactions
residing within the active-site or dimer interface. Thus, a single mutation within either of these regions
may render a whole class of compounds inactive. This observation emphasises the need for the
discovery of second and third generation IN inhibitors of novel structure and inhibition mechanisms.
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